Journal Article

Open-Source Automated Insulin Delivery in Type 1 Diabetes

Burnside, Mercedes J., Price, Sarah K.J., Meier, Renee A., Faherty, Ann M., Williman, Jonathan A., Sanders, Olivia J., Frewen, Carla M., Lewis, Dana M., Lever, Claire S., Crocket, Hamish R., Lampey, Christina, Wheeler, Benjamin J., Paul, Ryan G., Gunn, Tim C., de Bock, Martin I., Jefferies, Craig A., Jones, Shirley D.

2022

Overview

Open-source automated insulin delivery (AID) systems are used by many patients with type 1 diabetes. Data are needed on the efficacy and safety of an open-source AID system. In this multicenter, open-label, randomized, controlled trial, we assigned patients with type 1 diabetes in a 1:1 ratio to use an open-source AID system or a sensor-augmented insulin pump (control). The patients included both children (defined as 7 to 15 years of age) and adults (defined as 16 to 70 years of age). The AID system was a modified version of AndroidAPS 2.8 (with a standard OpenAPS 0.7.0 algorithm) paired with a preproduction DANA-i insulin pump and Dexcom G6 CGM, which has an Android smartphone application as the user interface. The primary outcome was the percentage of time in the target glucose range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter) between days 155 and 168 (the final 2 weeks of the trial). A total of 97 patients (48 children and 49 adults) underwent randomization (44 to open-source AID and 53 to the control group). At 24 weeks, the mean (±SD) time in the target range increased from 61.2±12.3% to 71.2±12.1% in the AID group and decreased from 57.7±14.3% to 54.5±16.0% in the control group (adjusted difference, 14 percentage points; 95% confidence interval, 9.2 to 18.8; P<0.001), with no treatment effect according to age (P = 0.56). Patients in the AID group spent 3 hours 21 minutes more in the target range per day than those in the control group. No severe hypoglycemia or diabetic ketoacidosis occurred in either group. Two patients in the AID group withdrew from the trial owing to connectivity issues. In children and adults with type 1 diabetes, the use of an open-source AID system resulted in a significantly higher percentage of time in the target glucose range than the use of a sensor-augmented insulin pump at 24 weeks. (Supported by the Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12620000034932.).

• Publisher: Massachusetts Medical Society
• Subject: Adolescent / Adolescent Medicine / Adult / Age / Aged / Algorithms / Allergy / Australia / Autoimmune Disease / Autoimmune diseases / Automation / Blood Glucose - analysis / Child / Childhood Diseases / Children / Clinical Medicine / Clinical trials / Diabetes / Diabetes mellitus (insulin dependent) / Diabetes Mellitus, Type 1 - blood / Diabetes Mellitus, Type 1 - drug therapy / Diabetic ketoacidosis / Endocrinology / Glucose monitoring / Hemoglobin / Humans / Hypoglycemia / Hypoglycemic Agents - administration & dosage / Immunology / Infusion Pumps / Insulin / Insulin - administration & dosage / Ketoacidosis / Middle Aged / Outpatient-Based Clinical Medicine / Patients / Pediatrics / Pediatrics General / Regulatory approval / Sensors / Smartphones / Teenagers / Young Adult